<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="924">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348448</url>
  </required_header>
  <id_info>
    <org_study_id>CANASCOV</org_study_id>
    <nct_id>NCT04348448</nct_id>
  </id_info>
  <brief_title>Observational Study, Use of Canakinumab Administered Subcutaneously in the Treatment COVID-19 Pneumonia</brief_title>
  <official_title>Observational Study on the Use of Canakinumab Administered Subcutaneously in the Treatment of Patients With COVID-19 Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AUSL Romagna Rimini</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AUSL Romagna Rimini</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is configured as a retrospective and prospective observational study. The study
      will be multi-center and will involve all COVID-19 pneumonia patients treated with
      canakinumab administered subcutaneously.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>intensive care treatment</measure>
    <time_frame>9 months</time_frame>
    <description>percentage of patients treated with canakinumab sc who do not require intensive care treatment during hospitalization for COVID-19</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU stay times</measure>
    <time_frame>9 months</time_frame>
    <description>ICU stay times</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% died after 1 month after treatment</measure>
    <time_frame>9 months</time_frame>
    <description>percentage of patients who died 1 month after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalization</measure>
    <time_frame>9 months</time_frame>
    <description>time of hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse event</measure>
    <time_frame>9 months</time_frame>
    <description>number of adverse event</description>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canakinumab 150 MG/ML [Ilaris]</intervention_name>
    <description>COVID-19</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with COVID 19
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with COVID 19 who have received or are candidates to receive treatment with
             canakinumab subcutaneously

          -  Age&gt; 18 years

          -  Pneumonia diagnosed with Chest X-ray / or Chest CT

        Exclusion Criteria:

          -  Patients with Covid19-related pathology in the context of another cause of major
             admission (trauma, surgery)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

